Ncam1 Knockout cell line (MC38)
Catalog Number: KO01067
Price: Online Inquiry
Catalog Number: KO01067
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Ncam1 Knockout cell line (MC38) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epitheloid, semi-adherent semi-suspension cells |
Passage ratio | 1:2-1:4 |
species | Mouse |
Gene | Ncam1 |
Gene ID | 17967 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90% DMEM+10%FBS |
Parental Cell Line | MC38 |
Quality Control | Genotype: Ncam1 Knockout cell line (MC38) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | neural cell adhesion molecule 1provided by MGI |
Also known as | CD56; Ncam; E-NCAM; NCAM-1 |
Gene Description | Predicted to enable LRR domain binding activity and phosphatase binding activity. Involved in commissural neuron axon guidance; epithelial to mesenchymal transition; and regulation of semaphorin-plexin signaling pathway. Acts upstream of or within several processes, including homotypic cell-cell adhesion; positive regulation of calcium-mediated signaling; and regulation of exocyst assembly. Located in several cellular components, including external side of plasma membrane; growth cone; and neuronal cell body. Is expressed in several structures, including embryo mesenchyme; genitourinary system; nervous system; sensory organ; and skin. Human ortholog(s) of this gene implicated in several diseases, including alcohol dependence; bipolar disorder; drug dependence; middle cerebral artery infarction; and nicotine dependence. Orthologous to human NCAM1 (neural cell adhesion molecule 1). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Biased expression in CNS E18 (RPKM 29.9), whole brain E14.5 (RPKM 28.6) and 10 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.